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esponsibility of InstAbstract Eukaryotic elongation factor 2 kinase (eEF2K) inhibitors may aid in the development of new
therapeutic agents to combat cancer. Puriﬁed human eEF2K was obtained from an Escherichia coli
expression system and a luminescence-based high-throughput screening (HTS) assay was developed using
MH-1 peptide as the substrate. The luminescent readouts correlated with the amount of adenosine
triphosphate remaining in the kinase reaction. This method was applied to a large-scale screening
campaign against a diverse compound library and subsequent conﬁrmation studies. Nine initial hits
showing inhibitory activities on eEF2K were identiﬁed from 56,000 synthetic compounds during the HTS
campaign, of which, ﬁve were chosen to test their effects in cancer cell lines.
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Protein is the most important structural and functional macro-
molecule in the cell, therefore, the process of translation (also
called protein synthesis), which translates a messenger RNA
(mRNA) into a protein, is essential in this regard. Protein synthesis
is usually divided into three main stages: initiation, elongation and
termination1. The initial stage involves a variety of translation
initiation factors that work coordinately to provide stringent
regulatory mechanisms of translation. The elongation stage con-
sumes a large amount of energy and amino acids within cells to
synthesize new polypeptide chain, which will undergo further
post-translational modiﬁcation and fold into correct quaternary
structure to function in the cell. Indeed, more than 99% of the
energy and nutrients used in protein synthesis are consumed
during elongation. Studies on translation termination mainly focus
on abnormal signals and their effects on mRNA degradation while
the understanding of other aspects of this step is rather limited2.
Human eukaryotic elongation factor 2 (eEF2) is a member of
the GTP-binding translation factor family that promotes the
movement of ribosome along mRNA from one codon to the
next3,4. During the elongation stage, eEF2 facilitates the transloca-
tion of peptidyl-tRNA from ribosome A site to P site. eEF2 can be
phosphorylated and thus inactivated by human eEF2K5. The
phosphorylation of eEF2 plays an important role in the regulation
of protein synthesis. It was widely recognized that under stress
conditions such as nutrient starvation, hypoxia or acidosis, the
activity of eEF2K in tumor cells was upregulated which allows
tumor cells to adapt and survive in such an adverse microenviron-
ment. Thus, eEF2K has been proposed as a potential target for
cancer therapy.
Among the human kinome, the majority (90%) of protein
serine/threonine and tyrosine kinases share a similar architecture
within their catalytic domain, so they are classiﬁed as conventional
protein kinases (CPKs). The remainder (about 10%), which
displays little sequence homology with CPKs, are named as
atypical protein kinases (APKs). APKs and CPKs lack sequence
identity, but share a related catalytic core6 as well as a remarkably
similar N-terminal lobe that predominantly folds into a curved β-
sheet and contains the phosphate binding loop (P-loop). The inter-
lobe cleft serves as ATP binding pocket and possesses conserved
key catalytic residues7. Despite having similar ATP binding
pockets, the spatial location of their conserved region GXGXXG
is different. eEF2K is such an atypical Ser/Thr-protein kinase that
it was also known as ‘Ca2þ/CaM-kinase III’. Human eEF2K is
composed of 725 amino acids.
It is well established that phosphorylation at Thr56 inactivates
eEF2 thereby regulating protein synthesis at the elongation step of
translation8,9. This mechanism appears crucial for cancer cell
survival as it reduces energy and amino acid consumption to help
them live through adverse conditions10. This point of view is
supported by studies on cellular microenvironment11 and meta-
bolic stress10 with breast cancer cells12,13. Since eEF2K is neither
a conventional protein kinase nor has other known substrates,
blockage of its action does not signiﬁcantly affect normal
biological processes. eEF2K inhibitors can become new drug
candidates for cancer therapy.
It was thought that an eEF2 peptide (amino acid sequence:
SARAGETRFTDTRKDE) containing the phosphorylation site
was the substrate of eEF2K. When tested in vitro, however, it
did not work efﬁciently. Scientists subsequently found two proteinkinases MHCK (myosin heavy chain kinase from Dictyostelium
discoideum) A and B, whose structures had considerable similarity
to eEF2K, could phosphorylate a 16 amino acid peptide MH-1
(amino acid sequence: RKKFGESEKTKTKEFL) in vitro, an
action that can be replicated by eEF2K14. Thus, MH-1 peptide
has been used as a surrogate substrate for eEF2K.
In this study, we developed and validated a luminescence-based
high-throughput screening (HTS) assay for the identiﬁcation of
eEF2K inhibitors by use of MH-1 peptide. Traditional method to
detect the catalytic activities of protein kinase is to quantify the
incorporation of radioactive γ-phosphate form [γ-32P] adenosine
triphosphate (ATP) into a peptide or protein substrate by using a
scintillation counter. This is impracticable for HTS application.
Immunoblotting assay can also be employed in screening, but the
sample preparation is complex and costs time and money: it is
therefore not suitable for HTS and could be readily replaced by
ﬂuorescence and luminescence approaches. MH-1 peptide sub-
strates have been commercialized. For instance, ADP-GloTM
luminescent kinase assay kit can eliminate redundant ATP in the
assay system and transform ADP into ATP effectively. This
became the key technology used in this study.2. Materials and methods
2.1. Reagents
A484954, eEF2K enzyme produced and puriﬁed from Escherichia
coli according to the method previously described15 and calmo-
dulin were provided by Professor C. Proud at South Australia
Health and Medical Research Institute. MH-1 peptide was
purchased from China Peptides Co., Ltd. (Shanghai, China).
EDTA, EGTA, CaCl2 and MgCl2 were bought from Shanghai
Chemical Reagents Co., Ltd. (Shanghai, China). 3-(N-morpholino)
propanesulfonic acid (MOPS), DMSO and β-mercaptoethanol (β-
ME) were obtained from Sigma (St Louis, MO, USA). The assay
plates were the products of PerkinElmer (Boston, MA, USA).
ADP-GloTM luminescent kinase assay kit was procured from
Promega (Wisconsin, MA, USA). The anti-eEF2 and anti-
phospho-eEF2 antibodies were purchased from Cell Signaling
Technologies (Boston, MA, USA). L15 medium, fetal bovine
serum, penicillin, streptomycin, sodium pyruvate, geneticin and
0.5% trypsin–EDTA were bought from Life Technologies (Carls-
bad, CA, USA). Cancer cell lines used in this study were obtained
from ATCC (Manassas, VA, USA).
2.2. Cell culture
MDA-MB-453 cells were maintained in L15 medium containing
10% fetal bovine serum (FBS), 100 units/mL penicillin/strepto-
mycin, 1 mmol/L sodium pyruvate and 0.5 mg/mL geneticin
without CO2. H1299 cells and HCT116 cells were maintained in
RPMI-1640 medium and McCoy's 5a medium containing 10%
FBS, respectively, 100 U/mL penicillin/streptomycin, 1 mmol/L
sodium pyruvate and 0.5 mg/mL geneticin in a 5% CO2 incubator.
2.3. Compound library
The compound library used for the screening of eEF2K inhibitors
is consisted of 56,000 pure synthetic compounds. The stock was
HTS for eEF2K inhibitors 559presolubilized in 100% DMSO prior to application in the HTS
campaign with an average concentration of 1 mg/mL for each
compound. The purity (95% minimum) of all compounds was
documented and randomly veriﬁed by the Chinese National
Compound Library.
2.4. Luminescence-based HTS campaign
Before the primary screening, assays were performed manually in
solid white 384 square well plates (BD Bioscience, NJ, USA).
Serial dilutions of each reagent (enzyme, ATP and unlabeledFigure 1 Optimization of a luminescence-based HTS assay against
eEF2K. (A) Reaction time. (B) Enzyme concentration and room
temperature storage time. (C) Z0 factor of the assay was determined
at the optimized assay conditions. The background (closed circles)
represents luminescence in 2% DMSO (negative control) and the
signal (open circles) indicates that in 25 mmol/L of A484954 (positive
control). Values given in A and B are means7SEM. RLU, relative
luminescence unit.peptide MH-1) were made to determine the optimal experimental
conditions, which led to the selection of 6 ng/mL and 100 mmol/L
for eEF2K and MH-1, respectively. In detail, we selected a 10 mL
reaction volume. 4 μL of assay mixture 2 (MH-1 and ATP diluted
in H2O) was ﬁrst dispensed by Bravo liquid handler (Agilent, CA,
USA) to an assay plate. 2 mL of compounds (1 mg/mL) were
diluted with 18 mL 1 kinase buffer in 96 square well plates, then
transferred (2 mL) to the 384 square well plates as described above.
4 μL of assay mixture 1 (eEF2K, β-ME and calmodulin diluted in
1 kinase buffer) was then dispensed to each well of the 384
square well plates. Enzyme was ﬁrst mixed with compounds to
initiate the reaction prior to incubation at room temperature (RT)
for 2 h. The reaction was stopped by 10 mL of ADP-GloTM reagent
from the ADP-GloTM luminescent kinase assay kit followed by
incubation at RT for at least 40 min. At last, 10 mL of kinase
detection reagent was introduced and incubated at RT for 30 min.
Luminescence was measured with an EnVision plate
reader and the emission ﬁlter used was luminescence 700
(PerkinElmer).
Hits identiﬁed from the primary screening were hand-picked
(5 mg/mL in DMSO) and serially diluted (1:3) seven times to give
a total of eight different concentrations. Each compound was
tested in duplicate and the dose-response characteristics were
analyzed using GraphPad Prism software (GraphPad, San Diego,
CA, USA) for nonlinear regression analysis.2.5. Western blot
Cells were seeded in 24-well plates at 2 105 cells/well. Twenty-
four hours later, they were treated with A484954 and hit com-
pounds for 6 h, rinsed once with Dulbecco's phosphate-buffered
saline (D-PBS) and harvested in 2 SDS-PAGE loading buffer
(TakaRa, Dalian, China). Cell lysates were incubated at 95 1C
for 10 min and then resolved in Criterion XT 10% gels (Bio-Rad,
Hercules, CA, USA) for at least 60 min. Proteins were transferred
to an Immobilon FL PVDF membrane (Millipore, Merck KGaA,
Darmstadt, Germany) in 1 transfer buffer for 40 min. The
membranes were rocked gently in blocking buffer (5% skimmed
milk) and probed with primary antibodies to phospho-eEF2
at Thr56 and eEF2 at 4 1C overnight. The antibody against
β-actin was from Life Technologies. Detection of primary anti-
bodies was performed using Alexa Fluor 680 against rabbit
secondary antibodies from Invitrogen. Image acquisition andFigure 2 The experiment was performed under the optimized assay
conditions and the IC50 calculated from the concentration–response
curve of A484954 is 0.23 mmol/L. RLU, relative luminescence unit.
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(Bio-Rad).2.6. Statistical analysis
All results were analyzed by using Prism 5 (GraphPad). Z0 factor is
a simple statistical parameter for HTS assay, whereas signal-to-
background ratio (S/B) is to assess assay quality. Data variation is
analyzed by standard deviation (SD) or coefﬁcient of variationFigure 3 Results of high-throughput screening campaign against
eEF2K. Distribution of potential hits identiﬁed from 56,000 small
molecule compounds is expressed as percentage inhibition of each
sample compared with the positive control (A484954).
Table 1 Conﬁrmed hits showing consistent inhibition of eEF2
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this study were calculated as below.
Z0 ¼ 13 SDPCþSDNC
MeanPCMeanNCjj
ð1Þ
S=B¼ Mean signal
Mean background
ð2Þ
CV %ð Þ ¼ SD=Mean  100 ð3Þ
Inhibition %ð Þ ¼ 1 SignaltestSignalNC
SignalPCSignalNC
 
 100 ð4Þ
where PC represents positive control wells; NC represents negative
control wells; SD represents standard deviation, M represents
mean.3. Results
3.1. Assay optimization
A number of assay parameters that may affect signals evoked by
kinase reaction and background noises were studied. In order to
ascertain the optimal incubation time, we detected the ﬁnal
luminescence signal at different times after initiation of the assayK activity in vitro.
Figure 4 Western blot analysis of hit compounds in cancer cells.
(A) Effect of WNN0048-A002 on eEF2K in MDA-MB-453 cells. The
breast cancer cell line was treated with different concentrations of the
compound for 6 h. Cell lysates were analyzed by western blotting
using antibodies speciﬁc for phospho-eEF2 (Th-56). β-Actin was used
as a loading control. P-eEF2, eEF2 phosphorylation. (B) Histogram of
the western blotting analysis data shown as mean 7SEM from three
independent experiments in duplicate.
HTS for eEF2K inhibitors 561with appropriate enzyme and superﬂuous substrate. Since a
reaction time of 2 h gave a good signal window it was set as an
optimized incubation period (Fig. 1A). Considering that there is a
time postponement between ﬁrst and last batch of samples during
the HTS process and kinase at RT may be unstable, we diluted the
enzyme (initial concentration was 0.05 mg/mL) by 1:2–1:7 differ-
ent concentration gradients and placed them at RT for 0, 2 and 4 h,
respectively, before adding to the assay plate to activate the
reaction. In this condition, according to the luminescence signal
shown in Fig. 1B, 0.00625 mg/mL (or 6 ng/mL) enzyme displayed
acceptable response which was thus set as an optimal concentra-
tions. Other reagents such as β-ME, ATP and calmodulin were
introduced according to the amounts described above. Finally,
DMSO (blank) and compound A484954 (positive control) were
employed to calculate Z0 factor (0.73), S/B ratio (15.78) and CV
(7%) values (Fig. 1C), which suggest that our assay system is of
high quality and suitable for HTS.
After optimizing the assay conditions, we studied
concentration-dependent response features of A484954. An IC50
value of 0.23 mmol/L, consistent with that reported in the
literature17 (0.28 mmol/L), was obtained (Fig. 2).3.2. HTS campaign
We applied 56,000 compounds from the Chinese National
Compound Library to a large-scale random screening against
eEF2K. Distribution of inhibition is illustrated in Fig. 3. Only nine
initial hits showing inhibition over 25% were identiﬁed. They were
hand-picked and rescreened using the same assay in duplicates.
Five compounds (WNN0017-C003, WNN0048-A002, WNN0532-
H011, WNN0572-A011 and WNN0593-D007) displaying consis-
tent inhibition on eEF2K (430%) were conﬁrmed and further
studied for their concentration–response characteristics (Table 1)
and effects on cancer cell lines.3.3. Effects on cells
A484954 is a highly selective eEF2K inhibitor with an IC50 value of
0.28 mmol/L in an enzymatic assay while having little activity against
a wide panel of other serine/threonine and tyrosine kinases17. Our
Western blot data (Fig. 4) demonstrate that A484954 was capable of
inhibiting eEF2 phosphorylation in MDA-MB-453, H1299 and
HCT116 cells. Due to limited compound availability, we selected
WNN0048-A002 (purity495%) as a representative to investigate
its activity in MDA-MB-453 cells. WNN0017-C003 was used
as a negative control. Surprisingly, both compounds increased
the phosphorylation of eEF2 (p-eEF2) in the cell and the total protein
level of eEF2 was not affected by either A484954 or hit compound
treatment.4. Discussion
In this paper, we presented a robust a luminescence-based
enzymatic assay applicable to an HTS setting (Fig. 1). When used
to screen a large collection of 56,000 synthetic compounds, it only
identiﬁed 9 initial hits and 5 of them were subsequently conﬁrmed
(Fig. 3 and Table 1). It appears that the hit rate against eEF2K in
our screening system is rather low although the assay parameters
investigated such as Z0 factor, S/B ratio and CV values are all
optimal. The underlying reasons responsible for this phenomenon
may be explained by data from additional HTS campaigns with
more diverse compound libraries.
Another interesting observation relates to inhibition of eEF2
phosphorylation by the newly discovered eEF2K inhibitors.
Unlike the positive control (A484954), both WNN0048-A002
and WNN0017-C003 were unable to show such an effect, but
instead, they promoted eEF2 phosphorylation in MDA-MB-453
breast cancer cells (Fig. 4). At this time we do not understand why
this happened and whether it was due to a non-speciﬁc effect of
these compounds or they hit other targets in the signaling path-
ways upstream of eEF2K. Extending the investigation to other
conﬁrmed hits may provide some clues. It should be noted that
eEF2K is activated under a wide range of stress conditions.
To date, some small molecule eEF2K inhibitors have been
reported. They are summarized and compared in terms of the
experimental methods led to their discovery in Table 218–24.
Rottlerin is mainly used as a selective inhibitor of protein kinase
Cδ. It was found to activate calcium and potassium ion channels
and to inﬂuence the function of mitochondria, thus can also be
used as an eEF2K inhibitor18,25. 1,3-selenazine analogs react with
cysteine residues in cells thereby preventing eEF2 phosphorylation19.
NH125 is a widely accepted eEF2K inhibitor: it inhibits eEF2K
activity in vitro but promotes eEF2 phosphorylation in vivo11,20.
Thieno [2,3-b] pyridine is an ATP-competitive inhibitor with weak
inhibitory effects on eEF2K in cells22. Thiopyran dicarbonitrile
analogs are a class of eEF2K inhibitors discovered by HTS23.
Finally, A484954 employed in this study is also an ATP-
competitive inhibitor23 possessing a good inhibitory effect on
eEF2K in vitro but rather low potency in cells. It is also cytotoxic
at high concentrations26.
Clearly, there exists an unmet demand for novel eEF2K inhibitors
which can inhibit eEF2K effectively but have low or none cell
cytotoxicity. In this regard, our work with eEF2K is just a beginning
on the road to validate if it is an ideal target for cancer therapy.
Table 2 Summary of identiﬁed eEF2K inhibitors.
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(1-[6-[(3-acetyl-2,4,6-trihydroxy-5-
methylphenyl)methyl]-5,7-
dihydroxy-2,2-dimethyl-2H-1-
benzopyran-8-yl]-3-phenyl-2-
propen-1-one, mallotoxin) 
(4-ethyl-4-hydroxy-2-p-tolyl-5,
6-dihydro-4H-1,3-selenazine) 
(4-hydroxy-6-isopropyl-4-methyl-
2-p-tolyl-5,6-dihydro-4H-1, 3-selenazine) 
(1-benzyl-3-cetyl-2-methylimi-
dazolium iodide) 
(3-amino-4-(furan-2-yl)-6,7,8,9,
10,11-hexahydro-5H-cyclonona
[b]thieno[3,2-e]pyridine-2-car-
boxamide) 
2,6-Diamino-4-(2-fluorophenyl)-4H-
thiopyran-3,5-dicarbonitrile 
2-((3-Cyano-4-(4-methoxyphenyl)
pyridine-2-ylthio)-2-
phenylacetic) acid 
(7-amino-1-cyclopropyl-3-ethyl-
1,2,3,4-tetrahydro-2,4-dioxopyrido
[2,3-d]pyrimidine-6-carboxamide) 
(2-((3,5-dimethyl-4-hydroxyphenyl)-
methylene)-4-cyclopentene-1,3-dione) 
-
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